NRF1 mitigates motor dysfunction and dopamine neuron degeneration in mice with Parkinson's disease by promoting GLRX m6A methylation through upregulation of METTL3 transcription
CNS Neuroscience & Therapeutics2023Vol. 30(3), pp. e14441–e14441
Citations Over TimeTop 10% of 2023 papers
Abstract
Conclusively, NRF1 constrained motor dysfunction and dopamine neuron degeneration in MPTP-induced PD mice by activating the METTL3/GLRX axis.
Related Papers
- → Acute and Chronic 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Administrations Elicit Similar Microglial Activation in the Substantia Nigra of Monkeys(2009)45 cited
- → Co-Expression of Nogo-A in Dopaminergic Neurons of the Human Substantia Nigra Pars Compacta Is Reduced in Parkinson’s Disease(2021)7 cited
- → Expression of c-Jun in dopaminergic neurons of the substantia nigra in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice(1997)33 cited
- → Morphological parameters of the heterogeneity of the substantia nigra in elderly men and women(2015)3 cited
- Quantitative research on FA value of substantia nigra pars compacta in early Parkinson′s disease(2014)